Protective role of Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukaemia and COVID-19.
作者信息
Thibaud Santiago, Tremblay Douglas, Bhalla Sheena, Zimmerman Brittney, Sigel Keith, Gabrilove Janice
机构信息
Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Division of Infectious Diseases, Icahn School of Medicine at Mount Sinaii, New York, NY, USA.
出版信息
Br J Haematol. 2020 Jul;190(2):e73-e76. doi: 10.1111/bjh.16863. Epub 2020 Jun 4.
Abstract
摘要
相似文献
1
Protective role of Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukaemia and COVID-19.布鲁顿酪氨酸激酶抑制剂在慢性淋巴细胞白血病合并新型冠状病毒肺炎患者中的保护作用
Br J Haematol. 2020 Jul;190(2):e73-e76. doi: 10.1111/bjh.16863. Epub 2020 Jun 4.
2
The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients.布鲁顿酪氨酸激酶（BTK）抑制剂依鲁替尼可能对新冠病毒感染患者的肺损伤具有保护作用。
Blood. 2020 May 21;135(21):1912-1915. doi: 10.1182/blood.2020006288.
3
BTK Inhibitors in Cancer Patients with COVID-19: "The Winner Will be the One Who Controls That Chaos" (Napoleon Bonaparte).在感染 COVID-19 的癌症患者中使用 BTK 抑制剂：“胜者将是那个能控制住混乱局面的人”（拿破仑·波拿巴）。
Clin Cancer Res. 2020 Jul 15;26(14):3514-3516. doi: 10.1158/1078-0432.CCR-20-1427. Epub 2020 Apr 28.
4
BTK Inhibitors in Chronic Lymphocytic Leukemia.布鲁顿酪氨酸激酶抑制剂在慢性淋巴细胞白血病中的应用。
Curr Hematol Malig Rep. 2021 Oct;16(5):422-432. doi: 10.1007/s11899-021-00645-1. Epub 2021 Oct 2.
5
CLL and COVID-19 at the Hospital Clinic of Barcelona: an interim report.巴塞罗那医院诊所的慢性淋巴细胞白血病与新冠疫情：中期报告
Leukemia. 2020 Jul;34(7):1954-1956. doi: 10.1038/s41375-020-0870-5. Epub 2020 May 19.
6
Bringing hospital care closer to patients amidst COVID-19.在新冠疫情期间让医院护理更贴近患者。
Lancet Haematol. 2020 Sep;7(9):e637. doi: 10.1016/S2352-3026(20)30259-3.
7
Outcomes of COVID-19 in patients with CLL: a multicenter international experience.慢性淋巴细胞白血病患者感染新型冠状病毒肺炎的结局：一项多中心国际经验
Blood. 2020 Sep 3;136(10):1134-1143. doi: 10.1182/blood.2020006965.
8
COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus.慢性淋巴细胞白血病患者的 COVID-19 严重程度和死亡率：ERIC、欧洲慢性淋巴细胞白血病研究倡议和 CLL 校园的联合研究。
Leukemia. 2020 Sep;34(9):2354-2363. doi: 10.1038/s41375-020-0959-x. Epub 2020 Jul 9.
9
Inhibition of Bruton tyrosine kinase in patients with severe COVID-19.在重症 COVID-19 患者中抑制布鲁顿酪氨酸激酶。
Sci Immunol. 2020 Jun 5;5(48). doi: 10.1126/sciimmunol.abd0110.
10
Oral Bruton tyrosine kinase inhibitors selectively block atherosclerotic plaque-triggered thrombus formation in humans.口服布鲁顿酪氨酸激酶抑制剂选择性阻断人类动脉粥样硬化斑块触发的血栓形成。
Blood. 2018 Jun 14;131(24):2605-2616. doi: 10.1182/blood-2017-09-808808. Epub 2018 Mar 20.
引用本文的文献
1
Meta-analysis of mortality factors after COVID-19 infection in pediatric oncology patients.儿童肿瘤患者新冠病毒感染后死亡因素的荟萃分析
Front Oncol. 2025 Aug 6;15:1594617. doi: 10.3389/fonc.2025.1594617. eCollection 2025.
2
A randomized, placebo-controlled trial of the BTK inhibitor zanubrutinib in hospitalized patients with COVID-19 respiratory distress: immune biomarker and clinical findings.一项关于BTK抑制剂泽布替尼在新冠病毒肺炎呼吸窘迫住院患者中的随机、安慰剂对照试验：免疫生物标志物及临床发现
Front Immunol. 2025 Jan 21;15:1369619. doi: 10.3389/fimmu.2024.1369619. eCollection 2024.
3
The Immunomodulatory Mechanisms of BTK Inhibition in CLL and Beyond.布鲁顿酪氨酸激酶（BTK）抑制在慢性淋巴细胞白血病及其他疾病中的免疫调节机制
Cancers (Basel). 2024 Oct 23;16(21):3574. doi: 10.3390/cancers16213574.
4
Vaccine challenges in CLL: a comprehensive exploration of efficacy of SARS-CoV-2 immunization for patients with chronic lymphocytic leukemia.慢性淋巴细胞白血病的疫苗挑战：对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）免疫接种对慢性淋巴细胞白血病患者疗效的全面探索
Ann Hematol. 2024 Dec;103(12):4971-4980. doi: 10.1007/s00277-024-05869-8. Epub 2024 Jul 15.
5
The impact of Bruton's tyrosine kinase inhibitor treatment on COVID-19 outcomes in Chinese patients with chronic lymphocytic leukemia.布鲁顿酪氨酸激酶抑制剂治疗对中国慢性淋巴细胞白血病患者新冠病毒病结局的影响
Front Oncol. 2024 May 21;14:1396913. doi: 10.3389/fonc.2024.1396913. eCollection 2024.
6
COVID-19 in Patients with Chronic Lymphocytic Leukemia: What Have We Learned?慢性淋巴细胞白血病患者中的新冠病毒肺炎：我们了解到了什么？
Acta Haematol. 2024;147(1):60-72. doi: 10.1159/000534540. Epub 2023 Oct 11.
7
Safeguarding COVID-19 and cancer management: drug design and therapeutic approach.保障新冠疫情期间的癌症管理：药物设计与治疗方法
Open Res Eur. 2021 Jul 5;1:77. doi: 10.12688/openreseurope.13841.1. eCollection 2021.
8
Recent Advances in Covalent Drug Discovery.共价药物发现的最新进展
Pharmaceuticals (Basel). 2023 Apr 28;16(5):663. doi: 10.3390/ph16050663.
9
Anticancer Therapy and Mortality of Adult Patients with Hematologic Malignancy and COVID-19: A Systematic Review and Meta-Analysis.成人血液系统恶性肿瘤合并新型冠状病毒肺炎患者的抗癌治疗与死亡率：一项系统评价和荟萃分析
Life (Basel). 2023 Jan 30;13(2):381. doi: 10.3390/life13020381.
10
COVID-19 and atrial fibrillation: Intercepting lines.2019冠状病毒病与心房颤动：交叉防线
Front Cardiovasc Med. 2023 Jan 23;10:1093053. doi: 10.3389/fcvm.2023.1093053. eCollection 2023.
本文引用的文献
1
Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System.纽约医院系统中 COVID-19 癌症患者的病死率。
Cancer Discov. 2020 Jul;10(7):935-941. doi: 10.1158/2159-8290.CD-20-0516. Epub 2020 May 1.
2
The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients.布鲁顿酪氨酸激酶（BTK）抑制剂依鲁替尼可能对新冠病毒感染患者的肺损伤具有保护作用。
Blood. 2020 May 21;135(21):1912-1915. doi: 10.1182/blood.2020006288.
3
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.中国武汉地区 2019 年新型冠状病毒感染患者的临床特征。
Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24.
4
Improvement in Parameters of Hematologic and Immunologic Function and Patient Well-being in the Phase III RESONATE Study of Ibrutinib Versus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.在 III 期 RESONATE 研究中，伊布替尼对比奥法木单抗治疗先前治疗的慢性淋巴细胞白血病/小淋巴细胞淋巴瘤患者的血液学和免疫学功能参数及患者生存状况的改善。
Clin Lymphoma Myeloma Leuk. 2018 Dec;18(12):803-813.e7. doi: 10.1016/j.clml.2018.08.007. Epub 2018 Aug 18.
5
Inhibiting Bruton's tyrosine kinase rescues mice from lethal influenza-induced acute lung injury.抑制布鲁顿酪氨酸激酶可挽救小鼠免于致死性流感诱导的急性肺损伤。
Am J Physiol Lung Cell Mol Physiol. 2018 Jul 1;315(1):L52-L58. doi: 10.1152/ajplung.00047.2018. Epub 2018 Mar 8.
6
Serious Infections in Patients Receiving Ibrutinib for Treatment of Lymphoid Cancer.接受伊布替尼治疗淋巴癌患者的严重感染。
Clin Infect Dis. 2018 Aug 16;67(5):687-692. doi: 10.1093/cid/ciy175.
7
Ibrutinib withdrawal symptoms in patients with Waldenström macroglobulinemia.华氏巨球蛋白血症患者的依鲁替尼撤药症状。
Haematologica. 2018 Jul;103(7):e307-e310. doi: 10.3324/haematol.2017.186908. Epub 2018 Feb 22.
8
Systematic review of infectious events with the Bruton tyrosine kinase inhibitor ibrutinib in the treatment of hematologic malignancies.布鲁顿酪氨酸激酶抑制剂伊布替尼治疗血液系统恶性肿瘤相关感染事件的系统评价。
Eur J Haematol. 2018 Apr;100(4):325-334. doi: 10.1111/ejh.13020. Epub 2018 Feb 6.
9
Dysregulated Type I Interferon and Inflammatory Monocyte-Macrophage Responses Cause Lethal Pneumonia in SARS-CoV-Infected Mice.I型干扰素失调和炎性单核细胞-巨噬细胞反应导致SARS-CoV感染小鼠发生致命性肺炎。
Cell Host Microbe. 2016 Feb 10;19(2):181-93. doi: 10.1016/j.chom.2016.01.007.
10
Disruption of in vivo Chronic Lymphocytic Leukemia Tumor-Microenvironment Interactions by Ibrutinib--Findings from an Investigator-Initiated Phase II Study.依鲁替尼对体内慢性淋巴细胞白血病肿瘤微环境相互作用的破坏——一项研究者发起的II期研究结果
Clin Cancer Res. 2016 Apr 1;22(7):1572-82. doi: 10.1158/1078-0432.CCR-15-1965. Epub 2015 Dec 9.
Zotero 插件